Last reviewed · How we verify
Beovu
At a glance
| Generic name | Beovu |
|---|---|
| Also known as | Brolucizumab |
| Sponsor | Novartis Pharmaceuticals |
| Target | Vascular endothelial growth factor A |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
Common side effects
- Vision blurred
- Cataract
- Conjunctival hemorrhage
- Eye pain
- Vitreous floaters
- Intraocular inflammation
- Intraocular pressure increased
- Retinal hemorrhage
- Vitreous detachment
- Conjunctivitis
- Retinal pigment epithelial tear
- Corneal abrasion
Key clinical trials
- Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PHASE3)
- Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (NA)
- Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
- Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (PHASE4)
- Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
- Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (PHASE4)
- Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
- Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beovu CI brief — competitive landscape report
- Beovu updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI